Last reviewed · How we verify
LY2541546
At a glance
| Generic name | LY2541546 |
|---|---|
| Also known as | Blosozumab |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY2541546 in Women With Low Bone Mineral Density (PHASE2)
- A Study of LY2541546 in Healthy Postmenopausal Women (PHASE1)
- A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women (PHASE1)
- A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women (PHASE1)
- A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2541546 CI brief — competitive landscape report
- LY2541546 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI